

Quaking-5 suppresses aggressiveness of lung cancer cells through inhibiting β -catenin signaling pathway


SUPPLEMENTARY MATERIALS



Supplementary Figure 1: QKI-5 is the dominant isoform of QKIs expressed in LC cells. (A) Schematic representation of the exon organization of five *QKI* isoforms generated by alternative splicing of exon6-exon8 annotated by NCBI. Gray boxes indicate 5' or 3' untranslated regions. Two pairs of RT–PCR primers flanking exons 6 and 7 (blue arrows) theoretically produce five splicing isoforms with respective length. (B) *QKI* mRNA splicing pattern in LC cell lines (A549, SPC-A1, H661) analyzed by RT–PCR using two primer pairs (blue arrows in **A**). Ful-gels showed that *QKI-5* was the dominant isoform. (C) Western blotting detection of QKI protein expression in the indicated LC cells. The results showed that QKI-5 was the dominant isoform.




Supplementary Figure 2: QKI mRNA expression correlates with the prognosis of LC patients. Kaplan-Meier analysis of the correlation between the level of *QKI* mRNA and overall survival of 1926 LC patients from the Kaplan Meier plotter (http://www. kmplot.com).




Supplementary Figure 3: Expression of QKI-5 is decreased in LC cell lines. (A) *QKI-5* mRNA expression in two pairs of LC cell lines with different metastatic potentials (AGZY vs ANIP, 95C vs 95D). The data are presented as the mean \pm SD. **P*<0.05, ***P*<0.01. (B) Western blotting analyses of QKI-5 and mesenchymal markers (N-cadherin, Vimentin) expressions in a panel of LC cell lines and the bronchial epithelial cell (Beas2B). α -tubulin was used as the loading control.

Oncotarget, Supplementary Materials 2017



Supplementary Figure 4: The inhibitory effects of QKI-5 on the migration and invasion of SPC-A1 cells. (A and **B**) Detections of qRT-PCR (A) and Western blotting (B) of QKI-5 overexpression and knockdown efficiencies in stable SPC-A1 subcell lines constructed with the indicated viruses or plasmids. The *QKI-5* mRNA level was normalized against *GAPDH*. The ratios of *QKI-5/GAPDH* in the vector and sh-NC groups were arbitrarily set to 1.0. (C) Migration and invasion abilities of the indicated SPC-A1 subcell lines assessed by wound-healing and transwell assays. All the experiments were performed at least in triplicate and the data in A and C are presented as the mean \pm SD. **P*<0.05, ***P*<0.001.



Supplementary Figure 5: QKI-5 overexpression inhibits the TGF- β 1-induced EMT of LC cells via interdicting β -catenin signaling pathway. (A) Representative images of A549-vector (control) and A549-QKI-5 (QKI-5-overexpressing) cells untreated or incubated with TGF- β 1 (5 ng/mL) for 48 h (×200). (B) mRNA levels of *E*-cadherin, *N*-cadherin, *Snail* and *Slug* in the indicated cells incubated with TGF- β 1 or untreated in DMEM for 72 h. (C) Protein levels of Snail and Slug determined by Western blotting in the indicated cells. (D) β -catenin mRNA level in the indicated cells; mock = blank control, sh-NC = Scr control, sh-QKI-5 = QKI-5 silence with shRNA. The mRNAs were detected by qRT-PCR and normalized against *GAPDH*. The ratios of the above mRNAs to *GAPDH* mRNA in mock cells were arbitrarily set to 1.0 and the data in B and D are presented as the mean \pm SD. ***P*<0.001, ****P*<0.001.

Supplementary Table 1: Clinical characteristics of all tested tissue samples

See Supplementary File 1

Name	Sequences
RT-PCR primers	
QKI exon5-Forward-1	5'-GGAGAAGACAGCCTGAAGAAGA-3'
QKI exon7-Reverse-1	5'-GTAAGGATGGACACGCATATCG-3'
QKI exon5-Forward-2	5'-AAGGAGAAGACAGCCTGAAGAA-3'
QKI exon7-Reverse-2	5'- TGGTAAGGATGGACACGCATAT-3'
β-catenin RIP-Forward	5'-CAGCTGTATTGTCTGAACTTGC-3'
β-catenin RIP-Reverse	5'-CACTTCTTGAGTCACTCCCAAA-3'
MSP primers	
QKI5 MSP-M-Forward	5'-TAATAAGATCGTTTTTTTAGAGGCG-3'
QKI5 MSP-M-Reverse	5'- CCGTAACTTCTTTCGATATTCGTA-3'
QKI5 MSP-U-Forward	5'- GGTGTAATAAGATTGTTTTTTAGAGGT-3
QKI5 MSP-U-Reverse	5'- CCATAACTTCTTTCAATATTCATA-3'

Supplementary Table 2: Sequences of RT-PCR and MSP primers

Name	Sequences
QKI-5-Forward	5'-AGCTGCCCTGCGTACTCCTA-3'
QKI-5-Reverse	5'-TGGGTGAGGAGTTCCGTTTG-3'
β-actin-Forward	5'-GATCATTGCTCCTCCTGAGC-3'
β-actin-Reverse	5'-ACTCCTGCTTGCTGATCCAC-3'
E-cadherin-Forward	5'-TTCCCTCGACACCCGATTC-3'
E-cadherin-Reverse	5'-GTCCCAGGCGTAGACCAAGA-3'
N-cadherin-Forward	5'-CCCCTTCACCCAACATGTTT-3'
N-cadherin-Reverse	5'-GTGGGATTGCCTTCCATGTC-3'
Vimentin-Forward	5'-GAACGCCAGATGCGTGAAAT-3'
Vimentin-Reverse	5'-CAGGCGGCCAATAGTGTCTT-3'
Snail-Forward	5'-ACCCCAATCGGAAGCCTAAC-3'
Snail-Reverse	5'-CGTAGGGCTGCTGGAAGGTA-3'
GAPDH-Forward	5'-CCACCCATGGCAAATTCCATGGCA-3'
GAPDH-Reverse	5'-TCTAGACGGCAGGTCAGGTCCACC-3'
β-catenin-Forward	5'-GGCTGGTGACAGGGAAGACAT-3'
β-catenin-Reverse	5'-TTCTGGGCCATCTCTGCTTCT-3'

Supplementary Table 3: Sequences of qRT-PCR primers

Supplementary Table 4: Sequences of QKI-5 cloning primers

Name	Sequences
pcDNA3.1-HindIII-Forward	5'-CCCAAGCTTATGGTCGGGGAAATGGAAACG-3'
pcDNA3.1-BamHI-Reverse	5'-CGCGGATCCTTAGTTGCCGGTGGCGGCT-3'
pCMV-tag2b-BamHI-Forward	5'-CGCGGATCCATGGTCGGGGAAATGGAAAC-3'
pCMV-tag2b-HindIII-Reverse	5'-CCCAAGCTTTTAGTTGCCGGTGGCGGCT-3'
pMSCV-puro-BglII-Forward	5'-GGAAGATCTATGGTCGGGGAAATGGAAACG-3'
pMSCV-puro-EcoRI-Reverse	5'-CCGGAATTCTTAGTTGCCGGTGGCGGCT-3'

Supplementary Table 5: Sequences of shRNAs

Name	Sequences
sh-NC-Sense	5'-ccggTTCCTGGAACAATTGCTTTTACTCGAGTAAAAG CAATTGTTCCAGGAATTTTTg-3'
sh-NC-Antisense	5'-aatteAAAAATTCCTGGAACAATTGCTTTTACTCGAGT AAAAGCAATTGTTCCAGGAA-3'
sh-QKI-5-Sense	5'-ccggAAGCACCTACAGAGATGCCAACTCGAGTTGGCA TCTCTGTAGGTGCTTTTTTg-3'
sh-QKI-5-Antisense	5'-aatteAAAAAAAGCACCTACAGAGATGCCAACTCGAGT TGGCATCTCTGTAGGTGCTT-3'

Supplementary Table 6: Sequences of siRNAs

Name	Sequences
si-β-catenin-Sense	5'-CCCACUAAUGUCCAGCGUUdTdT-3'
si-β-catenin-Antisense	5'-AACGCUGGACAUUGUGGGAdTdT-3'
si-NC-Sense	5'-GGUGGAACAAUUGCUUUUAdTdT-3'
si-NC-Antisense	5'-UAAAAGCAAUUGUUCCACCdTdT-3'